Bioceltix

Bioceltix EBITDA per Employee

EBITDA per Employee of Bioceltix (BCX.WA) as of Oct 21, 2026.

EBITDA per Employee

-PLN

Last updated:

EBITDA per Employee of Bioceltix is 2026 - PLN. EBITDA per Employee of Bioceltix was 2025 - PLN. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bioceltix Stock analysis

What does Bioceltix do? Bioceltix SA focuses on research and development within the field of veterinary medicine, specifically targeting the treatment of companion animals. The company develops candidates for veterinary medicinal products by utilizing the immunomodulatory properties of mesenchymal stem cells as the active substance. This scientific approach allows the firm to conduct research and development works that facilitate clinical trials and the full registration of these medicinal products with the European Medicines Agency, adhering to standards similar to those for human medicines. Bioceltix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioceltix stock

On Eulerpool you can find the complete historical development of EBITDA per Employee Bioceltix since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Bioceltix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Bioceltix

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Bioceltix